roxatidine acetate has been researched along with Peptic Ulcer in 11 studies
roxatidine acetate: structure given in first source
Peptic Ulcer: Ulcer that occurs in the regions of the GASTROINTESTINAL TRACT which come into contact with GASTRIC JUICE containing PEPSIN and GASTRIC ACID. It occurs when there are defects in the MUCOSA barrier. The common forms of peptic ulcers are associated with HELICOBACTER PYLORI and the consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study reports preliminary results of a controlled, multicenter trial on the quality of ulcer healing induced by lansoprazole (LPZ) or roxatidine (R) in gastric ulcer (GU) or duodenal ulcer (DU) patients." | 9.08 | Quality of peptic ulcer healing induced by lansoprazole and roxatidine. ( Fujino, MA; Kobayashi, K; Morozumi, A; Ohtsuka, H; Sano, S; Suzuki, Y; Tachikawa, H; Uchida, N; Ueda, F; Yamamoto, Y, 1995) |
| "Roxatidine acetate is a histamine H2-receptor antagonist which, after almost complete oral absorption (greater than 95%), is rapidly converted to its active metabolite, roxatidine, by esterases in the small intestine, plasma and liver." | 6.38 | Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders. ( McTavish, D; Murdoch, D, 1991) |
| "This study reports preliminary results of a controlled, multicenter trial on the quality of ulcer healing induced by lansoprazole (LPZ) or roxatidine (R) in gastric ulcer (GU) or duodenal ulcer (DU) patients." | 5.08 | Quality of peptic ulcer healing induced by lansoprazole and roxatidine. ( Fujino, MA; Kobayashi, K; Morozumi, A; Ohtsuka, H; Sano, S; Suzuki, Y; Tachikawa, H; Uchida, N; Ueda, F; Yamamoto, Y, 1995) |
| "The effects of a new H2-receptor antagonist, roxatidine acetate, have been investigated in both clinical and pharmacodynamic trials in Europe and the United States." | 2.66 | Safety and efficacy of roxatidine acetate. Evidence from pharmacodynamic and clinical trials. ( Bender, W; Labs, R; Merki, HS, 1989) |
| "Roxatidine acetate is a histamine H2-receptor antagonist which, after almost complete oral absorption (greater than 95%), is rapidly converted to its active metabolite, roxatidine, by esterases in the small intestine, plasma and liver." | 2.38 | Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders. ( McTavish, D; Murdoch, D, 1991) |
| " Relationships between pharmacokinetic variables and each parameter related to hepatic functions were also investigated." | 1.31 | Pharmacokinetics of roxatidine acetate in patients with chronic liver disease. ( Takase, S; Tsutsumi, M; Ueshima, Y, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (27.27) | 18.7374 |
| 1990's | 6 (54.55) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Umegaki, E | 1 |
| Yoda, Y | 1 |
| Tokioka, S | 1 |
| Murano, M | 1 |
| Higuchi, K | 1 |
| Dammann, HG | 1 |
| Wolf, N | 1 |
| Burkhardt, F | 1 |
| Fujino, MA | 1 |
| Morozumi, A | 1 |
| Kobayashi, K | 1 |
| Ueda, F | 1 |
| Suzuki, Y | 1 |
| Uchida, N | 1 |
| Tachikawa, H | 1 |
| Sano, S | 1 |
| Ohtsuka, H | 1 |
| Yamamoto, Y | 1 |
| Raedsch, R | 1 |
| Daake, H | 1 |
| Eisold, H | 1 |
| Schreiber, H | 1 |
| Gorbauch, T | 1 |
| Kriech, W | 1 |
| Marazova, K | 1 |
| Klouchek, E | 1 |
| Popov, A | 1 |
| Ivanov, CH | 1 |
| Krushkov, I | 1 |
| Tsutsumi, M | 1 |
| Ueshima, Y | 1 |
| Takase, S | 1 |
| Okabe, S | 1 |
| Takagi, K | 1 |
| Igata, H | 1 |
| Kato, S | 1 |
| Shimosako, K | 1 |
| Yamaji, Y | 1 |
| Seiki, M | 1 |
| Murdoch, D | 1 |
| McTavish, D | 1 |
| Walt, RP | 1 |
| Merki, HS | 1 |
| Bender, W | 1 |
| Labs, R | 1 |
| Collins, JD | 1 |
3 reviews available for roxatidine acetate and Peptic Ulcer
| Article | Year |
|---|---|
Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders.
Topics: Animals; Drug Evaluation; Histamine H2 Antagonists; Humans; Peptic Ulcer; Piperidines | 1991 |
Clinical importance of the new H2-antagonists.
Topics: Animals; Famotidine; Histamine H2 Antagonists; Humans; Nizatidine; Peptic Ulcer; Piperidines; Thiazo | 1989 |
Therapeutic approach in patients with concomitant disease/drug--drug interactions (roxatidine acetate).
Topics: Anti-Ulcer Agents; Cimetidine; Drug Interactions; Histamine H2 Antagonists; Humans; Peptic Ulcer; Pi | 1988 |
4 trials available for roxatidine acetate and Peptic Ulcer
| Article | Year |
|---|---|
[Effective prevention of indomethacin-induced gastroduodenal mucosal lesions with roxatidine acetate].
Topics: Adult; Cross-Over Studies; Histamine H2 Antagonists; Humans; Indomethacin; Male; Peptic Ulcer; Piper | 1995 |
Quality of peptic ulcer healing induced by lansoprazole and roxatidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Duodenal | 1995 |
[Treatment of peptic ulcer in internal medicine practice. A multicenter comparative study with roxatidine and cimetidine].
Topics: Adolescent; Adult; Aged; Cimetidine; Female; Histamine H2 Antagonists; Humans; Male; Middle Aged; Pe | 1993 |
Safety and efficacy of roxatidine acetate. Evidence from pharmacodynamic and clinical trials.
Topics: Cimetidine; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; Histamine H | 1989 |
4 other studies available for roxatidine acetate and Peptic Ulcer
| Article | Year |
|---|---|
Protective effect of roxatidine against indomethacin-induced small intestinal mucosal injury in rats.
Topics: Animals; Anti-Ulcer Agents; Cimetidine; Disease Models, Animal; Famotidine; Histamine H2 Antagonists | 2010 |
Gastroprotective effect of MX1 (a novel salt of the active metabolite of roxatidine with a complex of bismuth and citric acid) against stress ulcers in rats.
Topics: Animals; Antacids; Anti-Ulcer Agents; Drug Combinations; Gastric Mucosa; Histamine H2 Antagonists; M | 1997 |
Pharmacokinetics of roxatidine acetate in patients with chronic liver disease.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Chronic Disease; Creatinine; Half-Life; Hepatit | 2001 |
Effects of a new histamine H2-receptor antagonist, Z-300, on gastric secretion and gastro-duodenal lesions in rats: comparison with roxatidine.
Topics: Acetamides; Administration, Oral; Animals; Dogs; Duodenum; Female; Gastric Acid; Gastric Mucosa; His | 1992 |